<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Sun, 26 Apr 2026 15:16:52 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[医学] 心臓の拍動が心臓での癌細胞の増殖を防ぐ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109743&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109743&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 26 Apr 2026 15:16:52 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109743&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 欧州でのより初期段階の前立腺癌へのPluvicto使用承認申請をNovartisが取り下げ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109742&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109742&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認申請</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 26 Apr 2026 10:03:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109742&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 意識変容薬（サイケデリック薬）を開発する3社に米国FDAが優先審査権利付与</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109741&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109741&amp;ref=rss</guid>
		<category>ビジネス / 世界の動き / アメリカ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 25 Apr 2026 17:05:07 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109741&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Ph2試験成績いまいちのMASH薬pemvidutideのPh3試験資金をAltimmune社が調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109740&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109740&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 25 Apr 2026 16:03:54 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109740&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 1歳未満〜32歳のDFNB9患者の10人に9人の聴力が遺伝子治療で改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109739&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109739&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 25 Apr 2026 10:28:52 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109739&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] TLR7活性化薬付き抗PD-L1抗体PF08046037をPfizerがPh1試験もろとも打ち切り</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109738&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109738&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験 || 開発 / 臨床試験 / 中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 16:55:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109738&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AbbVieのしわ取り薬trenibotulinumtoxinE (TrenibotE) を米国が承認せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109737&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109737&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 完全回答（Complete Response Letter）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 16:43:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109737&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Grace社のくも膜下出血薬GTx-104（nimodipine）を米国承認せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109735&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109735&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 完全回答（Complete Response Letter）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 14:50:53 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109735&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Regeneron社の難聴遺伝子治療Otarmeniを米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109734&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109734&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 12:37:13 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109734&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 治療を止めた後のHIV封じにHIV専門CD8+ T細胞がだいぶ貢献しているらしい</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109733&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109733&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 10:36:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109733&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] KeytrudaKeytrudaの乳癌治療効果を予測する末梢血の免疫指標を開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109732&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109732&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 10:18:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109732&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 異常HNRNPH2の生成を阻止するアンチセンスオリゴヌクレオチドがマウスで有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109731&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109731&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 09:40:33 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109731&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 嚢胞性線維症（CF）変異1717-1G&gt;Aを正す塩基編集手段開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109730&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109730&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 08:48:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109730&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 抗TREM2抗体が糖尿病マウスの虚血肢の治癒を助ける</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109729&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109729&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 07:51:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109729&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] MEK阻害薬cobimetinibが癌増殖を促すYAP-TEAD複合体の阻害作用も担うと判明</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109728&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109728&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 16:43:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109728&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Sanofiの抗CD38抗体Sarclisa皮下注射の米国承認審査期間3か月延長</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109727&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109727&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認申請</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 16:23:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109727&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] LillyがRigel社とのRIPK1阻害薬提携をすっかり打ち切る</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109726&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109726&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 16:11:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109726&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Googleと組んでMerck &amp; Coが勝手に働く人AIを標準装備する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109725&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109725&amp;ref=rss</guid>
		<category>技術 / 情報技術（IT） / 全般</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 14:53:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109725&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 再発型多発性硬化症（RMS）Ph3試験2つでのRocheのfenebrutinibの死亡率が高い</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109724&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109724&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 12:53:51 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109724&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 殆どがワクチン接種済みの外来コロナ患者にPfizerのPaxlovid無効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109723&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109723&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 10:33:09 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109723&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 脳出血患者の出血性/虚血性脳卒中の発生が低用量降圧薬3つひとまとめで減った</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109722&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109722&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 08:40:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109722&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Regeneron社のC5抑制siRNA薬cemdisiranが重症筋無力症に効いたPh3試験論文</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109721&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109721&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 22 Apr 2026 16:39:27 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109721&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 非複雑性尿路感染症のニトロフラントイン治療が最も有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109720&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109720&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 22 Apr 2026 16:14:04 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109720&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 先立つ治療がまだの膵癌患者の生存がActuate社のGSK-3β阻害薬で3か月ほど延長</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109719&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109719&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 22 Apr 2026 12:52:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109719&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 免疫系を支えるB細胞が運動能力を支えもする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109718&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109718&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 22 Apr 2026 12:04:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109718&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Rocheの抗IL-6薬Enspryngが自己免疫疾患MOGAD相手のPh3試験で目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109717&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109717&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 22 Apr 2026 11:28:46 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109717&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] サイケデリック薬の優先審査を米国トランプ大統領が命令</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109716&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109716&amp;ref=rss</guid>
		<category>ビジネス / 世界の動き / アメリカ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 22 Apr 2026 11:02:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109716&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] ModernaのインフルエンザとCOVID-19の両取りワクチンmCOMBRIAXを欧州承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109715&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109715&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 22 Apr 2026 09:46:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109715&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 腎癌初治療でのMerck &amp; CoのHIF-2α阻害薬Welireg追加の生存改善示せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109714&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109714&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 22 Apr 2026 09:37:36 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109714&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Merck &amp; Coの1日1回1錠服用2成分HIV薬Idvynso（イドビンソ）を米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109713&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109713&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 22 Apr 2026 08:01:23 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109713&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Biogenが抗CD38抗体felzartamabの全世界権利を手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109712&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109712&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 16:39:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109712&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Arcus社の抗TIGIT抗体domvanalimabのPh3試験がさらに中止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109711&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109711&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験 || 開発 / 臨床試験 / 中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 16:16:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109711&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AstraZenecaのC5補体阻害薬UltomirisのPh3試験でIgA腎症患者の蛋白尿低下</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109710&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109710&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 15:58:30 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109710&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 慢性閉塞性肺疾患患者へのAstraZenecaのtozorakimabのPh3試験3つ目成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109709&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109709&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 15:30:52 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109709&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Passage社の前頭側頭型認知症遺伝子治療の対照群あり無作為化試験をFDA要求</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109708&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109708&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 12:29:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109708&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Novo社の鎌状赤血球症薬etavopivatのPh3試験成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109707&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109707&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 12:02:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109707&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 体内仕立てCAR-TのKelonia社をLillyが最大70億ドルを払って買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109706&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109706&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 11:15:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109706&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ワクチン接種促進策のどの要素が有効かを同定</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109705&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109705&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 10:49:19 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109705&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] オピオイド依存症妊婦をブプレノルフィンで安全に治療しうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109704&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109704&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 10:28:23 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109704&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] インドでのPh3試験でワクチン2つVPM1002とImmuvacの結核予防効果示せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109703&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109703&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 09:35:18 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109703&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 吸入酸素濃度（FiO2）が低いことは腹部手術患者の肺を傷み難くするらしい</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109702&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109702&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 07:39:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109702&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 出産女性を支援者が励ましたところで母乳保育率は改善せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109701&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109701&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 21 Apr 2026 07:08:25 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109701&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 非転移上咽頭癌患者の内側咽頭後リンパ節(MRLN)抜き照射で嚥下機能が長く好調</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109700&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109700&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 20 Apr 2026 12:22:33 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109700&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 自宅ベースの訓練、注意、指導の取り組みで脳卒中患者の転倒が減少</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109699&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109699&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 20 Apr 2026 12:00:30 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109699&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 人工知能（AI）頼みの意思決定で脳卒中患者の経過が改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109698&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109698&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 20 Apr 2026 11:35:54 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109698&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] クレアチンとシスタチンCの両方を使う糸球体濾過率（GFR）予想がより正確</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109697&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109697&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 20 Apr 2026 11:26:07 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109697&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 慢性閉塞性肺疾患患者の呼吸器絡み入院の予測値BLISS開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109696&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109696&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 20 Apr 2026 11:13:37 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109696&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] キノコが作る抗酸化物質の一種の L-エルゴチオネイン（EGT） が生理痛を緩和</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109695&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109695&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 20 Apr 2026 08:35:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109695&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 川崎病の小児へのプレドニゾロン投与の冠動脈病変を減らす効果なし</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109694&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109694&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 19 Apr 2026 15:10:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109694&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 閉塞腸骨静脈のステント留置込み治療が深部静脈血栓症後の血栓後症候群に有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109693&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109693&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 19 Apr 2026 15:00:12 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109693&amp;ref=rss</comments>
	</item>
</channel>
</rss>
